Lena M. Wulfken

MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels

Lena M. Wulfken, Rudolf Moritz, Carsten‐Henning Ohlmann et al. · PLoS ONE · 2011 · 229 citations · Full text

Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma

Stefan Hauser, Lena M. Wulfken, Stefan Holdenrieder et al. · Cancer Epidemiology · 2012 · 100 citations

Prognostic Biomarkers, Urology, Genitourinary Cancer +13

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Jürgen C. Becker, Selma Ugurel, Ulrike Leiter et al. · The Lancet · 2023 · 63 citations

Tumor Immunology, Surgical Oncology, Nivolumab Versus Observation +10

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

Georg Lodde, Andrea Forschner, Jessica C. Hassel et al. · Cancers · 2021 · 26 citations · Full text

Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study

Georg Lodde, Jessica C. Hassel, Lena M. Wulfken et al. · European Journal of Cancer · 2023 · 20 citations

Medicine, Cancer Management, Melanoma +6